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stronger predictor of current suicide risk. No associations 
were found with polymorphisms within COMT and BDNF 
genes, whereas significant associations were found with 
variations in rs13515 (MAPK1) and rs6740584 (CREB1) 
polymorphisms. From a clinical perspective, our study 
proposes several clinical characteristics, such as increased 
depressive symptomatology, anxiety comorbidity, func-
tional disability and family history of suicidality, as cor-
relates associated with suicide. Genetic risk variants in 
MAPK1 and CREB1 genes might be involved in a dysregu-
lation of inflammatory and neuroplasticity pathways and 
are worthy of future investigation.
Keywords Depression · Bipolar · Mood disorder · 
Suicide · Single nucleotide polymorphism · Genetic 
association study
Introduction
Mood disorders include major depressive (MDD) and bipo-
lar (BD) disorders [1], common psychiatric conditions 
within the general population [2]. It has been estimated that 
up to 15 % of the population will experience at least one 
mood disorder episode during their lifetime [3], leading 
to moderate-to-severe impairment in working and social 
activities and accounting for a significant burden in terms 
of days lost. Although the majority of psychiatric diseases 
present an increased liability toward suicidal behavior [4], 
patients affected by mood disorders are exposed to the 
highest risk [5]: The mortality rates due to completed sui-
cide are up to 15 % in MDD [6, 7] and 10 % in BD [4]. 
A strong relationship connects mood disorder episodes, 
in particular depressive states, with suicidal ideation and 
attempt [8]. Therefore, the assessment of suicidal risk and 
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the prevention of suicide attempt in patients suffering from 
mood disorders is crucial, even if an accurate evaluation 
often remains a challenge for psychiatrists.
Both retrospective and prospective studies have inves-
tigated suicidality in mood disorder patients, identifying 
several predisposing factors. The main demographic fea-
ture involved in increasing risk of suicide attempts is the 
female gender, whereas males are more likely to have a 
completed suicide [9–11]. Clinical factors that increase the 
risk of suicide attempt include: early onset of disease [12], 
high severity of depressive episodes [13], longer period of 
undiagnosed and untreated illness [14] and discontinuation 
of antidepressants [15]. A considerable number of stud-
ies relate suicide attempts and completions to feelings of 
hopelessness and higher scores on subjective depression 
levels [16–21]. Higher levels of suicidal tendencies have 
been suggested as the best predictor of completed suicide 
[18]. An increased likelihood of a suicide attempt has been 
described in persons who have experienced adverse life 
events [22] and use tobacco [8]. Among bipolar patients, 
additional risk factors for suicide attempts are the pres-
ence of rapid-cycling and mixed states [23] and depressive 
episodes at onset [24]; on the contrary, preponderance of 
manic episodes appears to be a risk-reducing factor [25]. 
A previous history of suicide attempt is the most reliable 
single predictor of future suicidal behavior (both attempted 
and completed suicide) in patients affected by mood disor-
ders [20, 26–28]. Several comorbidities lead to an increased 
susceptibility toward suicidal conduct: anxiety disorders 
[23], eating disorders [29], alcohol and substance abuse 
[25, 30, 31], personality disorders [32] and anger-related/
impulsive temperamental tracts [33]. Finally, in patients 
with positive anamnesis for a suicide attempt, a family his-
tory of mental illness [20] and suicidal behavior [28] is fre-
quently found.
The heritability of completed suicide is about 40 % [34], 
with minor contribution of shared family environmental 
factors; nevertheless, the precise genetic predisposition 
has not been fully understood yet. Strong neurobiologi-
cal evidence points toward serotonergic and noradrenergic 
dysfunction [35–37]. Dysregulation in serotonin (5-HT) 
neurotransmission also appears to be related to impulsive–
aggressive behavior [38], which influences suicidal behav-
ior as an intermediate phenotype [39]. Genetic studies have 
identified several candidate genes involved in the dopamin-
ergic and other neurotransmitter pathways [40].
The catechol-O-methyltransferase (COMT) gene, 
located on chromosome 22, synthesizes an enzyme respon-
sible for the degradation of catecholamines. The most 
studied variant (rs4680) involves a valine–methionine sub-
stitution at codon 158 (Val158Met), resulting in a high or 
low functional activity of the enzyme [41]. In particular, 
Val/Val genotypes present 40 % higher enzymatic activity 
compared with Met/Met genotypes [42]. COMT effects 
can be modulated by exposure to stress, particularly in 
the pathophysiology of depressed mood and related neu-
rocognitive processes [43]. A meta-analysis conducted by 
Kia-Keating [44] found significant association between this 
variant and suicidal behavior. Nevertheless, more recent 
studies [45–48] reported no relationship between Val-
158Met and suicide. Other researchers [49–52] explored 
the link between Val158Met and personality traits, such 
as novelty seeking/extraversion trait and violent behavior, 
with mixed results. While mostly rs4680 has been exten-
sively investigated so far, other less examined variants 
within COMT gene could also alter the enzymatic effi-
ciency in catabolizing catecholamines [53, 54].
Another commonly studied gene is the brain-derived 
neurotrophic factor (BDNF) gene, located on chromosome 
11, and expressed in a high number of cerebral structures; it 
codes for a homodimeric protein which plays an important 
role in neuronal development and synaptic plasticity. BDNF 
has also been previously implicated in suicidal behavior 
[55]. A postmortem study detected reduced mRNA levels 
of BDNF in the prefrontal cortex and hippocampus of sui-
cide subjects [56] and a meta-analysis reported significantly 
lower serum BDNF levels in depressed patients, compared 
with healthy controls [57]; furthermore, successful antide-
pressant treatment leads to an increment in BDNF secretion 
[58]. The valine-66-methionine polymorphism (rs6265), 
resulting in a modulation of BDNF activity-dependent 
secretion [59], has been observed to be associated with BD 
[60, 61], especially in patients with rapid cycling [62, 63]. 
Nevertheless, three studies and a meta-analysis [64–67] 
demonstrated  a significant association between Met allele-
carrying genotypes and a higher risk of suicide attempts in 
depressed patients. Another meta-analysis reported better 
response to selective serotonin reuptake inhibitors (SSRI) 
treatment in depressed patients with heterozygous geno-
types for Val66Met, compared with homozygous genotypes 
[68]. A less studied polymorphism (rs11030101) within the 
BDNF gene has been previously associated with BD [69].
Two other, not well investigated, genes that could be 
implicated in the genetic susceptibility to suicide are the 
mitogen-activated protein kinase 1 (MAPK1) gene and the 
cyclic adenosine monophosphate response element-binding 
protein-1 (CREB1) gene. The MAPK1 gene, located on 
chromosome 22, encodes a member of the MAP kinase 
family. Of various MAPKs, extracellular signal-regulated 
kinase 1/2 (ERK1/2) is involved in neuronal proliferation 
and differentiation and synaptic plasticity [70, 71]. In addi-
tion, through the activation of nitric oxide and pro-inflam-
matory cytokines, it plays an important function in inflam-
matory processes [72]. Dysregulation in MAPK1 signaling 
pathway is involved in MDD and suicidal behavior [73]; 
an alteration of MAPK1 levels has been documented in the 
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frontal cortex of patients with schizophrenia, BD and MDD 
[74]. In rodents, decreased phosphorylation of ERK1/2 
induced depressive-like behavior [75], while treatment with 
fluoxetine increased the activity of ERK1/2 signaling and 
led to an alleviation of depressive symptoms [76]. Other 
studies showed an involvement of MAPK1 in relation 
to antidepressants [77], mood stabilizers [78] and antip-
sychotics [79]. These findings suggest a possible role of 
MAPK1 pathway in response to depression and exposure 
to stress; in support of this hypothesis, BDNF may improve 
depressive symptoms through the stimulation of ERK1/2 
signaling [80].
The CREB1 gene is situated on chromosome 2; it 
encodes a transcription factor member of the leucine zip-
per family of DNA-binding proteins, which is a down-
stream target of MAPK1 pathway [81]. There is a close 
association between MAPK1 and CREB1 as they are both 
involved in the regulation of neuronal plasticity and inflam-
matory pathways [82], which retain a fundamental role in 
the pathophysiology of MDD [75]. Furthermore, an associ-
ation between CREB1 and response to antidepressants [83] 
and mood stabilizers [84] has been found. Most impor-
tantly, two studies have shown that in postmortem brains 
of suicide subjects there are a decreased mRNA expression 
and functional parameters of CREB [85, 86], thereby sign-
aling that CREB-related genes may play an important role 
in suicide.
The aim of the present study was twofold. Firstly, we 
examined clinical factors associated with a history of sui-
cide attempt in a sample of 553 mood disorder patients; the 
selection of variables subject to study was based on factors 
arising from the literature. Secondly, we investigated in a 
subsample of 259 bipolar patients the association between 
several polymorphisms within COMT, BDNF, MAPK1 and 
CREB1 genes and suicide attempt status; the selection of 
these candidate genes is based on previous data suggesting 
their involvement in pathophysiologic mechanisms under-
lying suicidal behavior. Two single nucleotide polymor-
phisms (SNPs) (rs4680 and rs174696) within the COMT 
gene were examined: The former one is located in the cod-
ing exon, while the latter one belongs to the intron. We also 
examined four SNPs (rs6265, rs11030101, rs11030104 
and rs12273363) within the BDNF gene: The first is a 
functional polymorphism, while the second belongs to 
the 5′ untranslated region (5′-UTR); the other two SNPs 
are situated in the promoter region. Within the MAPK1 
gene, we tested four SNPs (rs6928, rs13515, rs3810608 
and rs8136867) for their association with suicide attempt 
status: The first two SNPs are placed in the 5′-UTR, while 
the latter two belong to the intronic sequence. We also 
examined four SNPs (rs889895, rs2254137, rs6740584 




The participants of the present study have been recruited 
between March 2004 and March 2009 within the ‘Psy Plu-
riel’ center, Centre Européen de Psychologie Médicale, and 
the Department of Psychiatry of Erasme Hospital (in- and 
outpatients) in Brussels. The assessment of mood disorder 
patients was completed using the software program ‘COPE-
Bipolar.COM’ (Clinical Outcome Measures for Bipolar 
Disorder), consisting of structured examination tools and 
immediate data capture. It is composed of 10 modules: 
each of them is dedicated to essential elements of unipolar 
and bipolar disorders, such as sociodemographic charac-
teristics, psychiatric antecedents, diagnosis and treatment, 
quality of life and functioning. Patients were included if 
they met DSM-IV criteria for a diagnosis of mood disorder 
(BD and/or MDD). Approximately 40 % of the patients had 
an illness onset during the previous 6 months before admis-
sion and were seeking treatment for the first time, whereas 
another 27 % of the sample had an illness onset of more 
than 5 years. Mental retardation, dementia, neurologic dis-
order and severe organic disease were exclusion criteria. 
Written informed consent was obtained from all partici-
pants in the study after local ethical committee approval 
was obtained. For a detailed description of the sample, see 
[87].
Assessments
Clinical interviews were conducted by specifically trained 
psychiatrists. Lifetime diagnosis, course of illness and 
comorbidities of patients were assessed on the basis of 
the Mini-International Neuropsychiatric Interview (MINI) 
[88]. Severity of mood symptoms of the most recent epi-
sode was assessed using the Hamilton Rating Scale for 
Depression (HDRS) [89], the Montgomery and Asberg 
Depression Rating Scale (MADRS) [90] and the Young 
Mania Rating Scale (YMRS) [91]. Severity of functional 
impairment subsequent to the psychiatric disease was 
assessed using the Sheehan Disability Scale (SDS) (Shee-
han 1983). The presence or absence of a previous suicide 
attempt was established according to the MINI. Current 
suicidal risk was also assessed with the MINI interview and 
coded as present or absent. Psychiatric familial antecedents 
were screened for each patient: familial history of MDD 
and BD in first-degree relatives and familial history of sui-
cide attempt in first- and second-degree relatives.
Genotyping Genomic DNA (gDNA) was purified 
from whole peripheral blood samples with an automated 
workstation (Maxwell, Promega) and checked for qual-
ity (260/280 ratio >1.6) and quantity (>15 ng/L) by a 
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small-scale spectrophotometer (Nanodrop, Thermo Scien-
tific). The genotyping was performed using 20 ng of gDNA 
on a Sequenom MassARRAY platform (Sequenom, Cali-
fornia, USA) together with the iPLEX assay (http://www.
sequenom.com). Genotyping was then performed accord-
ing to the manufacturer’s standard protocols. MassAR-
RAY Typer version 4.0 3.4 was used to read the extended 
mass and genotype calls. SNPs were selected following a 
series of criteria: relevant previous findings, MAF > 5 %, 
validated and tagging. For some SNPs, genotyping was 
performed by restriction fragment length polymorphism 
(RFLP), based on PCR followed by restriction enzyme 
analysis. Forward and reverse primers’ sequences are avail-
able upon request. Genotyping success rate was above 
95 %. Genotype data were available for 259 patients.
Statistical analysis
Statistical analysis was performed using Statistical Package 
for Social Science (SPSS, IBM 20.0); Chi-square (χ2) tests 
and Student’s t tests were used to compare groups with his-
tory or no history of suicide attempt(s) on a range of cate-
gorical and continuous variables. Logistic regressions were 




The presence or absence of a suicide attempt was the main 
outcome of interest. Within our sample (n = 553), 221 
patients (40 %) were affected by MDD, while 332 patients 
(60.0 %) were diagnosed with BD. The psychopathol-
ogy groups did not significantly differ with regard to the 
proportion of suicide attempters: In the MDD group 77 
(34.8 %) had a suicide attempt versus 136 (40.9 %) in the 
BD group [χ2(1) = 2.1, p = 0.15], so we merged the two 
groups in our analysis.
Sociodemographic features of the sample, stratified 
by suicide attempt status, are reported in Table 1. Suicide 
attempters were significantly younger than non-suicidal 
patients, and female patients were more likely to have 
attempted suicide in comparison with male ones. Mood 
disorder patients with low levels of education also had 
more suicide attempts compared with those with high edu-
cational background. Smoking habits (defined as the use 
of tobacco for a period of a month or more) were associ-
ated with suicide attempter status. The two groups did not 
significantly differ with regard to ethnicity or employment 
status, whereas a marginal significant difference (p = 0.05) 
was found with regard to marital status, wherein suicide 
attempters were less likely to be married or cohabiting.
Clinical characteristics
Clinical features of mood disorder episodes are described 
in Table 2a, stratified by suicide attempt status. Patients 
with positive anamnesis for suicide presented higher scores 
on HDRS and MADRS. Furthermore, we detected no asso-
ciation between suicide attempt and severity of the manic 
symptoms (YMRS). Suicide attempters also displayed 
poorer scores on functionality in working and studying 
activities, family and social life.
With regard to suicide attempt status and psychiatric 
comorbidities (Table 2b), we found an increased frequency 
of suicide attempters in mood disorder patients currently 
affected by anxiety disorders, in particular panic disorder, 
obsessive–compulsive disorder (OCD) and post-traumatic 
stress disorder (PTSD). The presence of any anxiety disor-
der was also associated with prior suicide attempts. With 
regard to physical disorders, there were no differences 
between suicide attempters and non-attempters on the prev-
alence of diabetes or thyroid disease (Table 2c). Finally, the 
presence of first- and second-degree relatives with suicidal 
behavior was associated with positive anamnesis for sui-
cide attempt, whereas family history of bipolar or unipolar 
mood disorder was not (Table 2d).
As a last step, in a logistic regression model with age 
and gender as covariates, we tested which clinical factors 
are predictive of current suicidal risk. Due to high multicol-
linearity, three models were yielded, one including anxiety 
disorders as predictors, one with the rest of the clinical fac-
tors and one with the SDS, which highly correlated with the 
presence of both anxiety disorders and depressive symp-
toms and was entered in a regression as a single predictor. 
Besides age and gender, which were significant predictors, 
the presence of panic disorder, PTSD, severe depressive 
symptoms and high functional disability increased the odds 
of having a current suicide risk. Results are reported in 
Table 3. Mood disorder diagnosis (MDD or BD) was also 
entered as a predictor in all models but was not significant 
(p > 0.6) (data not shown).
Genetic analyses
Table 4 shows the frequency distributions of all SNPs of the 
four genes (COMT, BDNF, MAPK1 and CREB1) stratified 
by suicide attempt status. We found a significant associa-
tion between MAPK1-rs13515 and suicide attempt status. 
Patients carrying the TT genotype were more likely to be 
suicide attempters, whereas the CC genotype was more fre-
quent among non-attempters. Further analyses showed that 
this pattern was mainly observed in the male group, with 
significant differences between genotypes [χ2(2) = 11.60, 
p = 0.003], whereas in females differences did not 
approach significance (p = 0.10). Allelic analyses showed 
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that the T allele was significantly more frequent among 
suicide attempters (frequency = 53 %) than among non-
attempters (frequency = 42 %), [χ2(1) = 6.46, p = 0.01]. 
All other SNPs of the MAPK1 gene were not associated 
with suicide attempt status.
With regard to the CREB1 gene, we also found a signifi-
cant association: The TC genotype of the rs6740584 was 
more frequent in suicide attempters, whereas the CC geno-
type was more frequent in non-attempters (Table 4). Fur-
ther analyses showed that this pattern was most prevalent in 
females, where we found significant genotype differences 
[χ2(2) = 6.19, p = 0.045], whereas in males differences did 
not reach significance (p = 0.10). Allelic analyses showed 
that the T allele of the same SNP was more frequent 
in suicide attempters, at the trend level of significance 
[χ2(1) = 3.12, p = 0.08]. The A allele of rs889895 was 
also more frequent among suicide attempters—the associa-
tion reached only trend level of significance [χ2(1) = 3.09, 
p = 0.08]. No association was found between suicide 
attempt status and the COMT Val158Met polymorphism, 
and neither with rs174696. Associations with all BDNF 
polymorphisms were also not significant.
Discussion
The present study explored several clinical and genetic fac-
tors in relation to suicide attempt history or current suicidal 
risk. History of a prior attempt is still considered one of the 
Table 1  Sociodemographic 
characteristics stratified by 
suicide attempt status, in the 
whole sample (MDD and BD 
patients)
Significant p values are in bold
SD standard deviation, df degrees of freedom
a One patient was excluded due to the lack of information
Suicide attempt 
(n = 213)
No suicide attempt 
(n = 340)
t df p value
Age (mean ± SD) 45.99 ± 14.48 48.88 ± 13.75 −2.346 548 0.019
N (%) N (%) χ2 df p value
Gender
Females 150 (70.8 %) 192 (56.6 %) 11.042 1 0.001
Ethnicity
Caucasian 204 (96.2 %) 325 (95.9 %) 1.131 4 0.889
Asian 2 (0.9 %) 2 (0.6 %)
African 5 (2.4 %) 10 (2.9 %)
North American 0 (0.0 %) 1 (0.3 %)
Latin-American 1 (0.5 %) 2 (0.3 %)
Educationa
Primary school 13 (6.3 %) 20 (6.0 %) 11.510 4 0.021
Secondary school 39 (18.8 %) 35 (10.4 %)
Higher level secondary school 57 (27.4 %) 88 (26.2 %)
Non-university higher education 48 (23.1 %) 113 (33.6 %)
University 51 (24.5 %) 80 (23.8 %)
Marital status
Married/cohabiting 87 (41.0 %) 172 (50.7 %) 9.354 4 0.053
Widowed 6 (2.8 %) 11 (3.2 %)
Separated 17 (8.0 %) 12 (3.5 %)
Single 76 (35.8 %) 100 (29.5 %)
Divorced 26 (12.3 %) 44 (13.0 %)
Professional status
Employed (full time) 62 (33.3 %) 135 (44.4 %) 9.312 5 0.097
Employed (part time) 23 (12.4 %) 34 (11.2 %)
Unemployed 54 (29.0 %) 81 (26.6 %)
Student 21 (11.3 %) 18 (5.9 %)
Volunteer work 2 (1.1 %) 1 (0.3 %)
Retired 24 (12.9 %) 35 (11.5 %)
Smoking (for a month or more) 133 (63.9 %) 173 (51.0 %) 8.717 1 0.003
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best predictors of future suicide [28]. Our analyses add to 
the prior literature by confirming several associations of 
factors related to a suicidal profile in a relatively large sam-
ple of mood disorder patients.
More specifically, with regard to age, our findings are 
in line with prior research, demonstrating the presence of 
higher suicide rates in younger patients, in both MDD [92, 
93] and BD [30, 94]. This can be explained by the asso-
ciation of early-onset affective disorders with more severe 
depressive symptoms and increased liability toward suicide 
[12], while in older patients somatic symptoms and cog-
nitive decline prevail [93]. Female patients had a higher 
suicide attempt rate, in line with prior literature. In fact, 
women often present non-suicidal self-injury [10], while 
in men suicidal behavior is frequently characterized by 
violent methods and higher lethality [9]. In addition, bipo-
lar women are more likely to display predominance of 
depressive polarity [9], a known risk factor for suicidality 
[28]. Nonetheless, another hypothesis has been proposed: 
Depressive status in females could be influenced by hor-
mone–brain associations [95]. In particular, pubertal hor-
monal changes may contribute to sensitize brain structures 
toward neurobiological and behavioral repercussions of 
exposure to stress, which is known to be involved in the 
pathophysiology of depressive mood [96]. With regard to 
education, patients with lower education were more likely 
to report history of suicide; this is probably related to 
poorer social and occupational functioning, in conjunction 
Table 2  Clinical characteristics, psychiatric comorbidities, physical diseases and family history stratified by suicide attempt status
Significant p values are in bold
df degrees of freedom, SD standard deviation, MADRS Montgomery–Asberg Depression Rating Scale, YMRS Young Mania Rating Scale
a Patients were excluded due to the lack of information. All disorders are assessed as current unless otherwise specified
Suicide attempt (n = 213) No suicide attempt (n = 340) t df p value
Mean ± SD Mean ± SD
a. Clinical characteristics
Hamilton total score (21 items) 15.95 ± 9.10 13.73 ± 8.29 2.893 528 0.004
MADRS total score 19.91 ± 11.78 16.73 ± 10.71 3.202 528 0.001
YMRS total score 3.51 ± 5.81 4.11 ± 6.36 −1.097 530 0.273
Sheehan’s Disability Scale 6.80 ± 2.29 6.11 ± 2.19 3.473 534 0.001
N (%) N (%) χ2 df p value
b. Psychiatric comorbidities
Panic disorder 40 (18.9 %) 37 (11.0 %) 6.643 1 0.010
Obsessive–compulsive disordera 27 (13.1 %) 25 (7.5 %) 4.528 1 0.033
Social phobia 26 (12.3 %) 33 (9.8 %) 0.807 1 0.369
Post-traumatic stress disorder 22 (10.4 %) 14 (4.2 %) 8.225 1 0.004
Generalized anxiety disorder 66 (31.1 %) 98 (29.2 %) 0.239 1 0.625
Anorexia nervosa 2 (0.9 %) 0 (0.0 %) 3.166 1 0.075
Bulimia nervosa 4 (1.9 %) 7 (2.1 %) 0.028 1 0.867
Any anxiety disorder (current) 109 (51.2 %) 138 (40.6 %) 5.937 1 0.015
Alcohol abuse 48 (22.5 %) 83 (24.6 %) 0.294 1 0.587
Drug abuse 8 (3.8 %) 10 (3.0 %) 0.267 1 0.606
Mood disorder with psychotic features (lifetime) 81 (38.6 %) 107 (32.2 %) 2.284 1 0.131
c. Physical diseases
Thyroid disease
 Hyperthyroidism 3 (1.4 %) 3 (0.9 %) 1.24 3 0.742
 Hypothyroidism 23 (11.1 %) 29 (8.7 %)
 Thyroid goiter 3 (1.4 %) 4 (1.2 %)
Diabetes 7 (3.4 %) 15 (4.5 %) 0.43 1 0.51
d. Familial history
MDD in first-degree relativesa 128 (66.7 %) 183 (61.0 %) 1.617 1 0.204
BD in first-degree relativesa 51 (30.4 %) 72 (25.4 %) 1.284 1 0.257
Suicide attempt in first- and second-degree relativesa 58 (36.0 %) 59 (22.2 %) 9.664 1 0.002
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with an earlier-onset mood disorder and early behavioral 
dysfunction [97]. Past suicide attempters were more likely 
to be current smokers, and this is also in line with other 
studies [8, 98].
With regard to clinical characteristics that are associated 
with suicide, we found higher depression severity in the 
suicide attempters group, consistently with recent literature 
[13, 20, 28] that indicates symptoms like hopelessness and 
longer periods spent in depressed mood as substantial risk 
factors for suicidality. In fact, suicide attempts in BD are 
more likely to occur during depressive and mixed phases 
of the illness [30]. Consistent with this, we did not observe 
any differences in the levels of manic symptoms. A higher 
degree of disability was observed in the suicide group, in line 
with other findings [99], and can be probably ascribed to a 
more severe clinical course of the disorder (including high 
comorbidity) and treatment-resistant traits. Indeed, patients 
with history of a suicide attempt were more likely to suf-
fer from a comorbid panic disorder, PTSD and OCD. High 
disorder comorbidity in suicide samples has been reported 
before in both depressed and bipolar patients [20, 23]; in 
particular, OCD [28] and obsessive–compulsive personal-
ity traits [1] have been associated with suicidal behavior. 
Comorbidity with panic disorder and PTSD was also asso-
ciated with a significant increase in current suicidal risk in 
our sample: Our findings are in line with a large-scale lon-
gitudinal study showing that patients affected by mood 
disorders and comorbid anxiety have an increased risk of a 
subsequent suicide attempt [100]. Mood disorder patients 
affected by comorbid anxiety are more susceptible to pre-
sent earlier onset of symptoms [101], increased recurrence of 
depressive episodes [102] and severe depressive psychopa-
thology [103]. Seeking auto-medication by means of alcohol 
and substance abuse [104, 105] may also elicit an additive 
risk on suicide outcome [101]. Finally, family history of sui-
cide was associated indeed with a higher likelihood of hav-
ing attempted suicide, in line with prior observations [106]. 
Interestingly, family history of BD or MDD was not associ-
ated with a suicide attempt status. Prior literature shows evi-
dence of an increased frequency of psychiatric conditions in 
the family of patients who committed suicide [107, 108] and 
in the family of attempters [106]; our observations are in the 
same direction but did not reach statistical significance. Our 
sample size has adequate power; thus, we conclude that prior 
psychiatric family history is not strongly associated with 
suicide attempt status in mood disorder patients, but family 
history of suicide is. We should also note that in our sam-
ple the percentage of suicide attempters in the MDD and BD 
groups did not differ significantly, which is contrary to prior 
observations that show higher suicide attempter rates in BD 
patients [109, 110]; however, no differences between the two 
groups have also been found [111].
Turning to the associations with genetic polymorphisms, 
we found no association between the COMT Val158Met 
Table 3  Logistic regression 
models examining predictors of 
current suicidal risk
Significant predictors are in bold
B SE p value OR 95 % CI for OR
Lower Upper
Model 1: logistic regression including sociodemographics and anxiety disorders as predictors
Age −0.014 0.007 0.033 0.986 0.973 0.999
Gender 0.441 0.193 0.022 1.555 1.064 2.270
Education 0.022 0.079 0.783 1.022 0.875 1.194
Panic disorder 1.276 0.358 <0.001 3.583 1.775 7.232
Obsessive–compulsive disorder 0.810 0.414 0.051 2.248 0.998 5.062
Post-traumatic stress disorder 1.099 0.557 0.049 3.001 1.007 8.942
Model 2: logistic regression including sociodemographics, depressive symptoms and family history as 
predictors
Age −0.022 0.009 0.012 0.979 0.962 0.995
Gender 0.304 0.233 0.191 1.355 0.859 2.138
Education 0.053 0.096 0.577 1.055 0.874 1.273
Smoke 0.427 0.232 0.065 1.532 0.973 2.413
Hamilton total score 0.106 0.015 <0.001 1.112 1.079 1.146
Familial history of suicide attempt 0.156 0.269 0.562 1.168 0.690 1.978
Model 3: logistic regression including sociodemographics Sheehan’s Disability Scale as predictor
Age −0.019 0.007 0.005 0.981 0.968 0.994
Gender 0.405 0.194 0.037 1.500 1.025 2.194
Education 0.074 0.080 0.354 1.077 0.921 1.259
Sheehan (mean) 0.222 0.043 <0.001 1.248 1.147 1.358
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polymorphism and history of suicide attempt, in line with 
negative findings from prior literature [45–48], supporting 
the hypothesis of an indirect modulation exerted by COMT 
through perhaps intermediate phenotypes that may increase 
the vulnerability toward suicidal behavior [39]. In fact, sev-
eral studies linked rs4680 to anger, aggressive and violent 
temperamental traits [51, 52], reward dependence [45] and 
novelty seeking/extraversion [49].
We also did not find any associations with the BDNF 
gene polymorphisms. A view of the literature shows mixed 
results: Some studies provide evidence of association 
between suicide and reduced levels of serum BDNF [112], 
along with a decrease in BDNF mRNA expression [56, 
113]. We found dissimilar results pertaining to the role of 
Val66Met in increasing suicidal risk [64, 65, 114, 115]. It 
has to be noted that although the majority of these studies 
point toward an association with suicidal behavior, negative 
studies are less likely to be published, resulting in publica-
tion bias.
To our knowledge, this is the first study suggesting an 
association of rs13515 (within MAPK1) and rs6740584 
(within CREB1) polymorphisms with suicide attempt in a 
sample of bipolar patients. A study conducted by Dwivedi 
[73] offers an accurate insight of the physiopathologic 
mechanism involving MAPK1/ERK1 pathway. Previous 
research showed that expression and activation of extra-
cellular signal-regulated kinase (ERK1/2) were lower in 
prefrontal cortex and hippocampus of suicide subjects 
affected by MDD [116]; the down-regulation was found 
to be associated with a decrease in ERK1/2 mRNA and 
protein levels. Studies conducted in rodents support 
these results, showing that the administration of a com-
pound which blocks activation of ERK1/2 produces mood 
Table 4  Distribution of genotypes on the four genes (COMT, BDNF, 
MAPK1 and CREB1) according to suicide attempt status
Suicide attempt 
N (%)





 AA 23 (23.2 %) 39 (26.7 %) 1.202 0.548
 GA 44 (44.4 %) 69 (47.3 %)
 GG 32 (32.3 %) 38 (26.0 %)
rs174696
 CC 3 (2.9 %) 2 (1.4 %) 3.702 0.157
 CT 41 (39.8 %) 44 (29.9 %)
 TT 59 (57.3 %) 101 (68.7 %)
BDNF
rs6265
 AA 3 (3.1 %) 5 (3.5 %) 0.379 0.827
 GA 25 (25.8 %) 41 (29.1 %)
 GG 69 (71.1 %) 95 (67.4 %)
rs11030101
 AA 25 (24.0 %) 38 (25.7 %) 0.791 0.673
 TA 53 (51.0 %) 80 (54.1 %)
 TT 26 (25.0 %) 30 (20.3 %)
rs11030104
 AA 63 (61.8 %) 85 (58.6 %) 0.248 0.883
 AG 35 (34.3 %) 54 (37.2 %)
 GG 4 (3.9 %) 6 (4.1 %)
rs12273363
 CC 3 (2.9 %) 3 (2.0 %) 0.259 0.878
 TC 25 (24.0 %) 38 (25.7 %)
 TT 76 (73.1 %) 107 (72.3 %)
MAPK1
rs6928
 CC 31 (30.4 %) 42 (28.0 %) 1.091 0.580
 GC 43 (42.2 %) 73 (48.7 %)
 GG 28 (27.5 %) 35 (23.3 %)
rs3810608
 AA 18 (17.1 %) 17 (11.7 %) 1.872 0.392
 AG 29 (27.6 %) 48 (33.1 %)
 GG 58 (55.2 %) 80 (55.2 %)
rs13515
 CC 14 (13.3 %) 42 (28.4 %) 9.240 0.010
 TC 70 (66.7 %) 88 (59.5 %)
 TT 21 (20.0 %) 18 (12.2 %)
rs8136867
 AA 7 (7.6 %) 12 (8.6 %) 0.357 0.837
 GA 23 (25.0 %) 39 (27.9 %)
 GG 62 (67.4 %) 89 (63.6 %)
CREB1
rs889895
 AA 63 (61.2 %) 71 (50.0 %) 3.003 0.223
 AG 27 (26.2 %) 48 (33.8 %)
Significant p values are in bold
Table 4  continued
Suicide attempt 
N (%)
No suicide  
attempt N (%)
χ2 p value
 GG 13 (12.6 %) 23 (16.2 %)
rs2254137
 AA 32 (30.2 %) 42 (28.0 %) 5.202 0.074
 CA 47 (44.3 %) 85 (56.7 %)
 CC 27 (25.5 %) 23 (15.3 %)
rs6740584
 CC 7 (6.7 %) 31 (20.8 %) 9.694 0.008
 TC 70 (67.3 %) 82 (55.0 %)
 TT 27 (26.0 %) 36 (24.2 %)
rs2551922
 AA 1 (0.9 %) 0 (0.0 %) 1.576 0.455
 GA 7 (6.6 %) 12 (7.9 %)
 GG 98 (92.5 %) 140 (92.1 %)
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disorder-related behavioral deficits [117], and that depres-
sive-like behavior is related to decreased levels of ERK1/2 
phosphorylation [75]. Our hypothesis is that a genetic 
variation of rs13515 within the 5′-UTR of MAPK1 gene, 
in particular the presence of TT genotype, could influence 
mRNA transduction, leading to a decrease in ERK1/2 syn-
thesis. The subsequent down-regulation of MAPK/ERK1 
signaling cascade may result in functional abnormalities 
within the prefrontal cortex and hippocampal regions of 
the brain, such as dysregulation in neuronal proliferation, 
synaptic plasticity and inflammatory responses.
The present report has several limitations. First of all, 
it is a cross-sectional study, not allowing for the deduc-
tion of causal relationships. Secondly, suicide risk was 
classified as a dichotomous trait, according to the pres-
ence or absence of a past suicide attempt. We chose to do 
so because history of a suicide attempt is a more stable 
risk trait [28] than current suicidal ideation, according to 
prior literature. However, we may have missed cases who 
have a high suicidal risk but have not performed an attempt 
before. Regarding the genetic results, the number of cases 
in our study may be low, therefore not providing enough 
power to detect significant associations, for example, with 
the BDNF/COMT genes. Also, major effects from single 
SNPs are unlikely [118]. Future meta-analyses will shed 
light on this matter. Positive results involving SNPs within 
MAPK1 and CREB1 genes (also the gender-specific find-
ings) should be considered as preliminary and are worthy 
of future investigation. Finally, no correction for multiple 
testing was applied despite the high number of investi-
gated variables; most results would not survive correction. 
However, given the exploratory nature of our study, we do 
not claim to report strong associations but only suggestive 
results which could be useful for further investigations or 
meta-analyses.
Conclusion
Suicidal behavior has a complex etiology, involving both 
genetic predisposition and exposure to environmental 
influences, aside from the presence of an underlying psy-
chiatric diagnosis. Our study provided suggestive data 
of variants within MAPK1 and CREB1 genes associated 
with suicide attempt status, whereas associations with 
variations in the COMT and BDNF Val/Met polymor-
phisms were not replicated in this sample. From a clini-
cal perspective, our study proposes several clinical char-
acteristics, such as increased depressive symptomatology, 
anxiety comorbidity, functional disability and family his-
tory of suicidality, as correlates associated with a suicide 
attempt status in a large sample of mood disorder patients. 
Current suicidal risk was also predicted by most of these 
factors, but current anxiety comorbidity increased the 
odds most significantly. Clinicians may consider these 
determinants in their treatment agenda, in order to moni-
tor such clinical factors and administer adequate thera-
peutic interventions to prevent recurrence of suicidal 
tendencies.
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